An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19Yiyue Ge, Jianyang Zeng, Tingzhong Tian et al.|Signal Transduction and Targeted Therapy|2021Cited by 204
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trialJingxin Li, Tao Zhu, Shipo Wu et al.|The Lancet Respiratory Medicine|2022Cited by 172
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19Yiyue Ge, Jianyang Zeng, Fang Wan et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 168
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Fengcai Zhu, Lihua Hou et al.|Nature Medicine|2022Cited by 163
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Ningshao Xia, Chunlan Zhuang et al.|The Lancet Respiratory Medicine|2022Cited by 140